Sigyn Therapeutics, Inc. (SIGY) stock
Close on Oct 19, 2026Market cap $48.16KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2025
Valuation
- Market cap
- $48.16K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$3.22M
- EPS, diluted
- -$2.01
- Book value per share
- -$3.69
- Diluted shares
- 2M
Trading
- Previous close
- $0.03
- Open
- $0.03
- Day's range
- $0.03 – $0.03
- Volume
- 3,109
- Average volume (20 days)
- 14,264
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | SIGY | S&P 500 | Difference | SIGY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.8% | +0.6% | −14.4 pts | ||
| 3 months | -25.0% | +3.4% | −28.4 pts | ||
| Year to date | -98.2% | +13.3% | −111.5 pts | ||
| 1 year | -98.5% | +16.6% | −115.1 pts | ||
| 3 years | -99.7% | +86.4% | −186.0 pts | -84.9% | +23.1% |
| 5 years | -99.8% | +81.9% | −181.7 pts | -72.3% | +12.7% |
Twelve years at a glance
Fiscal years 2013 to 2024 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sigyn Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Update
- Update
- Update
About Sigyn Therapeutics
Surgical & Medical Instruments & Apparatus
Sigyn Therapeutics, Inc. is a medical device company that develops extracorporeal blood purification technologies to address cancer and infectious disease disorders. The company’s portfolio includes platforms designed to enhance cancer treatments, including the ImmunePrep platform to optimize immunotherapeutic antibody delivery, ChemoPrep to improve chemotherapy delivery, and ChemoPure to lower treatment toxicity by removing off-target chemotherapy. Its lead candidate, Sigyn Therapy, is a single-use disposable device designed to extract pathogens, bacterial toxins, hepatic toxins, and inflammatory cytokines from blood plasma, targeting conditions such as viral infections, antibiotic-resistant bacteria, endotoxemia, and sepsis.
Company profile, executives and historySigyn Therapeutics stock: common questions
What is Sigyn Therapeutics's stock price?
SIGY closed at $0.03 on Oct 19, 2026, up 0.00% on the day.
What is Sigyn Therapeutics's market cap?
Sigyn Therapeutics was worth $48.16K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is SIGY's P/E ratio?
Sigyn Therapeutics lost money over the twelve months to Sep 30, 2025 (diluted EPS -$2.01), so it has no meaningful P/E ratio.
Does Sigyn Therapeutics pay a dividend?
No. Sigyn Therapeutics has not paid a cash dividend over the last twelve months.
How has SIGY stock performed over the past year?
Including dividends, SIGY returned -98.5% over the past year, against +16.6% for the S&P 500.
Who are Sigyn Therapeutics's competitors?
Companies most similar to Sigyn Therapeutics by business, industry and size include CTSO, ICU, RNXT, CERS, BJDX.
See a number that looks wrong?